Current Cancer Drug Targets


Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 10 Issue: 7, November

Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases

Volume:10   Issue: 7
Pp: 649-659
M. Salerno, E. Cenni, C. Fotia, S. Avnet, D. Granchi, F. Castelli, D. Micieli, R. Pignatello, M. Capulli, N. Rucci, A. Angelucci, A. Del Fattore, A. Teti, N. Zini, A. Giunti and N. Baldini
DOI: 10.2174/156800910793605767
Published on: 01 March, 2012

Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel

Volume:10   Issue: 7
Pp: 660-669
Z. Khan, N. Khan, A. K. Varma, R. P. Tiwari, S. Mouhamad, G. B.K.S. Prasad and P. S. Bisen
DOI: 10.2174/156800910793605866
Published on: 01 March, 2012

The Role of Oxidative Stress and Anti-Oxidant Treatment in Platinum- Induced Peripheral Neurotoxicity

Volume:10   Issue: 7
Pp: 670-682
V. A. Carozzi, P. Marmiroli and G. Cavaletti
DOI: 10.2174/156800910793605820
Published on: 01 March, 2012

Is Src a Viable Target for Treating Solid Tumours?

Volume:10   Issue: 7
Pp: 683-694
B. Elsberger, B. Stewart, O. Tatarov and J. Edwards
DOI: 10.2174/156800910793605802
Published on: 01 March, 2012

Modular Branched Neurotensin Peptides for Tumor Target Tracing and Receptor-Mediated Therapy: A Proof-of-Concept

Volume:10   Issue: 7
Pp: 695-704
C. Falciani, B. Lelli, J. Brunetti, S. Pileri, A. Cappelli, A. Pini, C. Pagliuca, N. Ravenni, L. Bencini, S. Menichetti, R. Moretti, M. De Prizio, M. Scatizzi and L. Bracci
DOI: 10.2174/156800910793605875
Published on: 01 March, 2012

Wnt/β-Catenin/LEF-1 Signaling in Chronic Lymphocytic Leukemia (CLL): A Target for Current and Potential Therapeutic Options

Volume:10   Issue: 7
Pp: 716-727
R. K. Gandhirajan, S. J. Poll-Wolbeck, I. Gehrke and K.-A. Kreuzer
DOI: 10.2174/156800910793605794
Published on: 01 March, 2012

New Insights of CTLA-4 into Its Biological Function in Breast Cancer

Volume:10   Issue: 7
Pp: 728-736
H. Mao, L. Zhang, Y. Yang, W. Zuo, Y. Bi, W. Gao, B. Deng, J. Sun, Q. Shao and X. Qu
DOI: 10.2174/156800910793605811
Published on: 01 March, 2012

Dynamic Simulations of Pathways Downstream of ERBB-Family, Including Mutations and Treatments: Concordance with Experimental Results

Volume:10   Issue: 7
Pp: 737-757
N. Castagnino, L. Tortolina, A. Balbi, R. Pesenti, R. Montagna, A. Ballestrero, D. Soncini, E. Moran, A. Nencioni and S. Parodi
DOI: 10.2174/156800910793605848
Published on: 01 March, 2012

DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy

Volume:10   Issue: 7
Pp: 758-771
K. Chikamori, A. G. Grozav, T. Kozuki, D. Grabowski, R. Ganapathi and M. K. Ganapathi
DOI: 10.2174/156800910793605785
Published on: 01 March, 2012

Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer

Volume:10   Issue: 7
Pp: 772-781
C. D'Alterio, C. Consales, M. Polimeno, R. Franco, L. Cindolo, L. Portella, M. Cioffi, R. Calemma, L. Marra, L. Claudio, S. Perdona, S. Pignata, G. Facchini, G. Carteni, N. Longo, L. Pucci, A. Ottaiano, S. Costantini, G. Castello and S. Scala
DOI: 10.2174/156800910793605839
Published on: 01 March, 2012

Cancer Therapy By Targeting Hypoxia-Inducible Factor-1

Volume:10   Issue: 7
Pp: 782-796
Y. Li and D. Ye
DOI: 10.2174/156800910793605857
Published on: 01 March, 2012